

MCQOPTIONS
Saved Bookmarks
This section includes 14 Mcqs, each offering curated multiple-choice questions to sharpen your Drug Biotechnology knowledge and support exam preparation. Choose a topic below to get started.
1. |
How to prevent hepatic first-pass metabolism for corticosteroids? |
A. | Providing intravenously |
B. | Providing orally |
C. | Form esters and ether products |
D. | By enhancing lipophilicity |
Answer» D. By enhancing lipophilicity | |
2. |
What is the prodrug of Trichloroethanol Cl3C-CH2OH? |
A. | <a href="https://www.sanfoundry.com/wp-content/uploads/2019/10/drug-biotechnology-questions-answers-applications-prodrug-q14a.png"><img alt="The prodrug of Trichloroethanol Cl3C-CH2OH - option a" class="alignnone size-full wp-image-250545" height="65" sizes="(max-width: 411px) 100vw, 411px" src="https://www.sanfoundry.com/wp-content/uploads/2019/10/drug-biotechnology-questions-answers-applications-prodrug-q14a.png" srcset="https://www.sanfoundry.com/wp-content/uploads/2019/10/drug-biotechnology-questions-answers-applications-prodrug-q14a.png 411w, https://www.sanfoundry.com/wp-content/uploads/2019/10/drug-biotechnology-questions-answers-applications-prodrug-q14a-300x47.png 300w" width="411"/></a> |
B. | <a href="https://www.sanfoundry.com/wp-content/uploads/2019/10/drug-biotechnology-questions-answers-applications-prodrug-q14b.png"><img alt="The prodrug of Trichloroethanol Cl3C-CH2OH - option b" class="alignnone size-full wp-image-250546" height="65" sizes="(max-width: 388px) 100vw, 388px" src="https://www.sanfoundry.com/wp-content/uploads/2019/10/drug-biotechnology-questions-answers-applications-prodrug-q14b.png" srcset="https://www.sanfoundry.com/wp-content/uploads/2019/10/drug-biotechnology-questions-answers-applications-prodrug-q14b.png 388w, https://www.sanfoundry.com/wp-content/uploads/2019/10/drug-biotechnology-questions-answers-applications-prodrug-q14b-300x50.png 300w" width="388"/></a> |
C. | <a href="https://www.sanfoundry.com/wp-content/uploads/2019/10/drug-biotechnology-questions-answers-applications-prodrug-q14c.png"><img alt="The prodrug of Trichloroethanol Cl3C-CH2OH - option c" class="alignnone size-full wp-image-250547" height="61" sizes="(max-width: 405px) 100vw, 405px" src="https://www.sanfoundry.com/wp-content/uploads/2019/10/drug-biotechnology-questions-answers-applications-prodrug-q14c.png" srcset="https://www.sanfoundry.com/wp-content/uploads/2019/10/drug-biotechnology-questions-answers-applications-prodrug-q14c.png 405w, https://www.sanfoundry.com/wp-content/uploads/2019/10/drug-biotechnology-questions-answers-applications-prodrug-q14c-300x45.png 300w" width="405"/></a> |
D. | <a href="https://www.sanfoundry.com/wp-content/uploads/2019/10/drug-biotechnology-questions-answers-applications-prodrug-q14d.png"><img alt="The prodrug of Trichloroethanol Cl3C-CH2OH - option d" class="alignnone size-full wp-image-250548" height="60" sizes="(max-width: 388px) 100vw, 388px" src="https://www.sanfoundry.com/wp-content/uploads/2019/10/drug-biotechnology-questions-answers-applications-prodrug-q14d.png" srcset="https://www.sanfoundry.com/wp-content/uploads/2019/10/drug-biotechnology-questions-answers-applications-prodrug-q14d.png 388w, https://www.sanfoundry.com/wp-content/uploads/2019/10/drug-biotechnology-questions-answers-applications-prodrug-q14d-300x46.png 300w" width="388"/></a> |
Answer» C. <a href="https://www.sanfoundry.com/wp-content/uploads/2019/10/drug-biotechnology-questions-answers-applications-prodrug-q14c.png"><img alt="The prodrug of Trichloroethanol Cl3C-CH2OH - option c" class="alignnone size-full wp-image-250547" height="61" sizes="(max-width: 405px) 100vw, 405px" src="https://www.sanfoundry.com/wp-content/uploads/2019/10/drug-biotechnology-questions-answers-applications-prodrug-q14c.png" srcset="https://www.sanfoundry.com/wp-content/uploads/2019/10/drug-biotechnology-questions-answers-applications-prodrug-q14c.png 405w, https://www.sanfoundry.com/wp-content/uploads/2019/10/drug-biotechnology-questions-answers-applications-prodrug-q14c-300x45.png 300w" width="405"/></a> | |
3. |
Which of the following will not be a limitation for prodrug design? |
A. | Formation of toxic product |
B. | An inert carrier can be cleaved off forming toxic product |
C. | Product cleaving off before reaching the target site |
D. | The cleaving of the carrier is also site-specific |
Answer» E. | |
4. |
Which of the following is not a disadvantage of site-specific drug delivery? |
A. | May lead to toxic effects on other non-target tissues |
B. | May get diluted |
C. | Less distribution time |
D. | No penetrable to the target tissue |
Answer» D. No penetrable to the target tissue | |
5. |
Why lipophilic drugs are absorbed easily? |
A. | Less hydrolysed |
B. | Favours passive diffusion |
C. | Dissolution rate high |
D. | Can easily merge with the cell membrane |
Answer» C. Dissolution rate high | |
6. |
Why carbenicillin cannot be given orally? |
A. | Tastes bad |
B. | Bad odour |
C. | Degraded by saliva |
D. | Hydrolysed easily |
Answer» E. | |
7. |
Which one of these is the best way to preserve drugs for intravenous use? |
A. | Lyophilisation |
B. | Drying |
C. | Freezing |
D. | In solution form |
Answer» B. Drying | |
8. |
Which of the following reduces the pain of injection? |
A. | If the drug precipitates |
B. | If the drug penetrates to the surrounding areas |
C. | If the solution is strongly acidic |
D. | More water-soluble drug |
Answer» E. | |
9. |
No drug cause damage to the gastric mucosa. |
A. | True |
B. | False |
Answer» C. | |
10. |
Which one of the following will be an example of changing the physical form of the drug to get a prodrug? |
A. | Ethyl mercaptan to 1,3-Diesters |
B. | Trichloroethanol to p-Acetamidobenzene ester |
C. | Ethyl mercaptan to phthalate esters |
D. | Chloramphenicol to palmitate ester |
Answer» B. Trichloroethanol to p-Acetamidobenzene ester | |
11. |
A liquid with high vapour pressure has a strong odour. |
A. | True |
B. | False |
Answer» B. False | |
12. |
How improvement of a drug in case of taste is done? |
A. | Injecting the drug so no taste related problems |
B. | Reducing the drug solubility in the saliva |
C. | Lower affinity for the taste receptors and making the drug sweet |
D. | Reducing drug solubility in saliva and lower affinity for taste receptors |
Answer» E. | |
13. |
Which of the following will be the pharmacokinetic application of prodrugs? |
A. | Improvement of taste |
B. | Improvement of odour |
C. | Site-specific drug delivery |
D. | Reduction in GI irritation |
Answer» D. Reduction in GI irritation | |
14. |
Which of the following will be a pharmaceutical application of prodrugs? |
A. | Enhancement of bioavailability |
B. | Reduction of toxicity |
C. | Improvement of odour |
D. | Site-specific drug delivery |
Answer» D. Site-specific drug delivery | |